Personalized Nutrition Market Size At Around US$ 38 Bn In 2030

The personalized nutrition market would grow at a CAGR of 15.49% over the predicted time frame. The market is expected to increase in value from US$ 12 Bn in 2022 to US$ 38 Bn in 2030.

The on personalized nutrition Market, which provides a business strategy, research & development activities, concise outline of the market valuation, valuable insights pertaining to market share, size, supply chain analysis, competitive landscape and regional proliferation of this industry.

Download Free Sample@ https://www.precedenceresearch.com/sample/1823

Report Scope of the Personalized Nutrition Market

Report Coverage	Details
Market Size by 2030	USD 38 Billion
Growth Rate from 2022 to 2030	CAGR of 15.49%
Largest Market Share in 2021	North America
Fastest Growing Region	Asia Pacific
Base Year	2021
Forecast Period	2022 to 2030
Segments Covered	Product, Application, End use, Dosage Forms, Disease, Geography

A recent report provides crucial insights along with application based and forecast information in the Global Personalized nutrition Market. The report provides a comprehensive analysis of key factors that are expected to drive the growth of this market. This study also provides a detailed overview of the opportunities along with the current trends observed in the Personalized nutrition market.

A quantitative analysis of the industry is compiled for a period of 10 years in order to assist players to grow in the market. Insights on specific revenue figures generated are also given in the report, along with projected revenue at the end of the forecast period.

Companies and Manufacturers Covered

The study covers key players operating in the market along with prime schemes and strategies implemented by each player to hold high positions in the industry. Such a tough vendor landscape provides a competitive outlook of the industry, consequently existing as a key insight. These insights were thoroughly analysed and prime business strategies and products that offer high revenue generation capacities were identified. Key players of the global Personalized nutrition market are included as given below:

Personalized nutrition Market Key Players

• DNA Fit 
• Superior Supplement Manufacturing 
• Metagenetics, Inc. 
• Asiamerica, Ingredients 
• Nutralliance, Inc. 
• Mixfix, Inc. 
• Barrington Nutritionals 
• Balchem Corporation 
• Arizona Nutritional Supplements 
• Maat Nutritionals 
• Natures Product Inc. 

Market Segments

 By Product

• Active Measurement
• Standard Measurement

By Application

• Standard Supplement
• Disease-based

By End use

• Direct-to-consumer
• Wellness & Fitness Centers
• Hospital & Clinics
• Institutions
• Food Delivery Services

By Dosage Forms

• Tablets
• Capsule
• Powders
• Liquids
• Others

By Disease 

• Customized to the needs of consumer 
• Fitness Goal Oriented Application 

By Geography

• North America
• U.S.
• Canada
• Europe
• U.K.
• Germany
• France
• Asia-Pacific
• China
• India
• Japan
• South Korea
• Malaysia
• Philippines
• Latin America
• Brazil
• Rest of Latin America
• Middle East & Africa (MEA)
• GCC
• North Africa
• South Africa
• Rest of the Middle East & Africa

Report Objectives

• To define, describe, and forecast the global personalized nutrition market based on product, and region
• To provide detailed information regarding the major factors influencing the growth of the market (drivers, opportunities, and industry-specific challenges)
• To strategically analyze micromarkets1 with respect to individual growth trends, future prospects, and contributions to the total market
• To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
• To forecast the size of market segments with respect to four main regions—North America, Europe, Asia Pacific and the Rest of the World (RoW)2
• To strategically profile key players and comprehensively analyze their product portfolios, market shares, and core competencies3
• To track and analyze competitive developments such as acquisitions, expansions, new product launches, and partnerships in the personalized nutrition market

Table of Content

 Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Personalized Nutrition Market 

5.1. COVID-19 Landscape: Personalized Nutrition Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Personalized Nutrition Market, By Product

8.1. Personalized Nutrition Market, by Product, 2022-2030

8.1.1. Active Measurement

8.1.1.1. Market Revenue and Forecast (2017-2030)

8.1.2. Standard Measurement

8.1.2.1. Market Revenue and Forecast (2017-2030)

Chapter 9. Global Personalized Nutrition Market, By Application

9.1. Personalized Nutrition Market, by Application, 2022-2030

9.1.1. Standard Supplement

9.1.1.1. Market Revenue and Forecast (2017-2030)

9.1.2. Disease-based

9.1.2.1. Market Revenue and Forecast (2017-2030)

Chapter 10. Global Personalized Nutrition Market, By End use 

10.1. Personalized Nutrition Market, by End use, 2022-2030

10.1.1. Direct-to-consumer

10.1.1.1. Market Revenue and Forecast (2017-2030)

10.1.2. Wellness & Fitness Centers

10.1.2.1. Market Revenue and Forecast (2017-2030)

10.1.3. Hospital & Clinics

10.1.3.1. Market Revenue and Forecast (2017-2030)

10.1.4. Institutions

10.1.4.1. Market Revenue and Forecast (2017-2030)

10.1.5. Food Delivery Services

10.1.5.1. Market Revenue and Forecast (2017-2030)

Chapter 11. Global Personalized Nutrition Market, By Dosage Forms

11.1. Personalized Nutrition Market, by Dosage Forms, 2022-2030

11.1.1. Tablets

11.1.1.1. Market Revenue and Forecast (2017-2030)

11.1.2. Capsule

11.1.2.1. Market Revenue and Forecast (2017-2030)

11.1.3. Powders

11.1.3.1. Market Revenue and Forecast (2017-2030)

11.1.4. Liquids

11.1.4.1. Market Revenue and Forecast (2017-2030)

11.1.5. Others

11.1.5.1. Market Revenue and Forecast (2017-2030)

Chapter 12. Global Personalized Nutrition Market, By Disease

12.1. Personalized Nutrition Market, by Disease, 2022-2030

12.1.1. Customized to the needs of consumer

12.1.1.1. Market Revenue and Forecast (2017-2030)

12.1.2. Fitness Goal Oriented Application

12.1.2.1. Market Revenue and Forecast (2017-2030)

Chapter 13. Global Personalized Nutrition Market, Regional Estimates and Trend Forecast

13.1. North America

13.1.1. Market Revenue and Forecast, by Product (2017-2030)

13.1.2. Market Revenue and Forecast, by Application (2017-2030)

13.1.3. Market Revenue and Forecast, by End use (2017-2030)

13.1.4. Market Revenue and Forecast, by Dosage Forms (2017-2030)

13.1.5. Market Revenue and Forecast, by Disease (2017-2030)

13.1.6. U.S.

13.1.6.1. Market Revenue and Forecast, by Product (2017-2030)

13.1.6.2. Market Revenue and Forecast, by Application (2017-2030)

13.1.6.3. Market Revenue and Forecast, by End use (2017-2030)

13.1.6.4. Market Revenue and Forecast, by Dosage Forms (2017-2030)

13.1.7. Market Revenue and Forecast, by Disease (2017-2030) 

13.1.8. Rest of North America

13.1.8.1. Market Revenue and Forecast, by Product (2017-2030)

13.1.8.2. Market Revenue and Forecast, by Application (2017-2030)

13.1.8.3. Market Revenue and Forecast, by End use (2017-2030)

13.1.8.4. Market Revenue and Forecast, by Dosage Forms (2017-2030)

13.1.8.5. Market Revenue and Forecast, by Disease (2017-2030)

13.2. Europe

13.2.1. Market Revenue and Forecast, by Product (2017-2030)

13.2.2. Market Revenue and Forecast, by Application (2017-2030)

13.2.3. Market Revenue and Forecast, by End use (2017-2030)

13.2.4. Market Revenue and Forecast, by Dosage Forms (2017-2030) 

13.2.5. Market Revenue and Forecast, by Disease (2017-2030) 

13.2.6. UK

13.2.6.1. Market Revenue and Forecast, by Product (2017-2030)

13.2.6.2. Market Revenue and Forecast, by Application (2017-2030)

13.2.6.3. Market Revenue and Forecast, by End use (2017-2030)

13.2.7. Market Revenue and Forecast, by Dosage Forms (2017-2030) 

13.2.8. Market Revenue and Forecast, by Disease (2017-2030) 

13.2.9. Germany

13.2.9.1. Market Revenue and Forecast, by Product (2017-2030)

13.2.9.2. Market Revenue and Forecast, by Application (2017-2030)

13.2.9.3. Market Revenue and Forecast, by End use (2017-2030)

13.2.10. Market Revenue and Forecast, by Dosage Forms (2017-2030)

13.2.11. Market Revenue and Forecast, by Disease (2017-2030)

13.2.12. France

13.2.12.1. Market Revenue and Forecast, by Product (2017-2030)

13.2.12.2. Market Revenue and Forecast, by Application (2017-2030)

13.2.12.3. Market Revenue and Forecast, by End use (2017-2030)

13.2.12.4. Market Revenue and Forecast, by Dosage Forms (2017-2030)

13.2.13. Market Revenue and Forecast, by Disease (2017-2030)

13.2.14. Rest of Europe

13.2.14.1. Market Revenue and Forecast, by Product (2017-2030)

13.2.14.2. Market Revenue and Forecast, by Application (2017-2030)

13.2.14.3. Market Revenue and Forecast, by End use (2017-2030)

13.2.14.4. Market Revenue and Forecast, by Dosage Forms (2017-2030)

13.2.15. Market Revenue and Forecast, by Disease (2017-2030)

13.3. APAC

13.3.1. Market Revenue and Forecast, by Product (2017-2030)

13.3.2. Market Revenue and Forecast, by Application (2017-2030)

13.3.3. Market Revenue and Forecast, by End use (2017-2030)

13.3.4. Market Revenue and Forecast, by Dosage Forms (2017-2030)

13.3.5. Market Revenue and Forecast, by Disease (2017-2030)

13.3.6. India

13.3.6.1. Market Revenue and Forecast, by Product (2017-2030)

13.3.6.2. Market Revenue and Forecast, by Application (2017-2030)

13.3.6.3. Market Revenue and Forecast, by End use (2017-2030)

13.3.6.4. Market Revenue and Forecast, by Dosage Forms (2017-2030)

13.3.7. Market Revenue and Forecast, by Disease (2017-2030)

13.3.8. China

13.3.8.1. Market Revenue and Forecast, by Product (2017-2030)

13.3.8.2. Market Revenue and Forecast, by Application (2017-2030)

13.3.8.3. Market Revenue and Forecast, by End use (2017-2030)

13.3.8.4. Market Revenue and Forecast, by Dosage Forms (2017-2030)

13.3.9. Market Revenue and Forecast, by Disease (2017-2030)

13.3.10. Japan

13.3.10.1. Market Revenue and Forecast, by Product (2017-2030)

13.3.10.2. Market Revenue and Forecast, by Application (2017-2030)

13.3.10.3. Market Revenue and Forecast, by End use (2017-2030)

13.3.10.4. Market Revenue and Forecast, by Dosage Forms (2017-2030)

13.3.10.5. Market Revenue and Forecast, by Disease (2017-2030)

13.3.11. Rest of APAC

13.3.11.1. Market Revenue and Forecast, by Product (2017-2030)

13.3.11.2. Market Revenue and Forecast, by Application (2017-2030)

13.3.11.3. Market Revenue and Forecast, by End use (2017-2030)

13.3.11.4. Market Revenue and Forecast, by Dosage Forms (2017-2030)

13.3.11.5. Market Revenue and Forecast, by Disease (2017-2030)

13.4. MEA

13.4.1. Market Revenue and Forecast, by Product (2017-2030)

13.4.2. Market Revenue and Forecast, by Application (2017-2030)

13.4.3. Market Revenue and Forecast, by End use (2017-2030)

13.4.4. Market Revenue and Forecast, by Dosage Forms (2017-2030)

13.4.5. Market Revenue and Forecast, by Disease (2017-2030)

13.4.6. GCC

13.4.6.1. Market Revenue and Forecast, by Product (2017-2030)

13.4.6.2. Market Revenue and Forecast, by Application (2017-2030)

13.4.6.3. Market Revenue and Forecast, by End use (2017-2030)

13.4.6.4. Market Revenue and Forecast, by Dosage Forms (2017-2030)

13.4.7. Market Revenue and Forecast, by Disease (2017-2030)

13.4.8. North Africa

13.4.8.1. Market Revenue and Forecast, by Product (2017-2030)

13.4.8.2. Market Revenue and Forecast, by Application (2017-2030)

13.4.8.3. Market Revenue and Forecast, by End use (2017-2030)

13.4.8.4. Market Revenue and Forecast, by Dosage Forms (2017-2030)

13.4.9. Market Revenue and Forecast, by Disease (2017-2030)

13.4.10. South Africa

13.4.10.1. Market Revenue and Forecast, by Product (2017-2030)

13.4.10.2. Market Revenue and Forecast, by Application (2017-2030)

13.4.10.3. Market Revenue and Forecast, by End use (2017-2030)

13.4.10.4. Market Revenue and Forecast, by Dosage Forms (2017-2030)

13.4.10.5. Market Revenue and Forecast, by Disease (2017-2030)

13.4.11. Rest of MEA

13.4.11.1. Market Revenue and Forecast, by Product (2017-2030)

13.4.11.2. Market Revenue and Forecast, by Application (2017-2030)

13.4.11.3. Market Revenue and Forecast, by End use (2017-2030)

13.4.11.4. Market Revenue and Forecast, by Dosage Forms (2017-2030)

13.4.11.5. Market Revenue and Forecast, by Disease (2017-2030)

13.5. Latin America

13.5.1. Market Revenue and Forecast, by Product (2017-2030)

13.5.2. Market Revenue and Forecast, by Application (2017-2030)

13.5.3. Market Revenue and Forecast, by End use (2017-2030)

13.5.4. Market Revenue and Forecast, by Dosage Forms (2017-2030)

13.5.5. Market Revenue and Forecast, by Disease (2017-2030)

13.5.6. Brazil

13.5.6.1. Market Revenue and Forecast, by Product (2017-2030)

13.5.6.2. Market Revenue and Forecast, by Application (2017-2030)

13.5.6.3. Market Revenue and Forecast, by End use (2017-2030)

13.5.6.4. Market Revenue and Forecast, by Dosage Forms (2017-2030)

13.5.7. Market Revenue and Forecast, by Disease (2017-2030)

13.5.8. Rest of LATAM

13.5.8.1. Market Revenue and Forecast, by Product (2017-2030)

13.5.8.2. Market Revenue and Forecast, by Application (2017-2030)

13.5.8.3. Market Revenue and Forecast, by End use (2017-2030)

13.5.8.4. Market Revenue and Forecast, by Dosage Forms (2017-2030)

13.5.8.5. Market Revenue and Forecast, by Disease (2017-2030)

Chapter 14. Company Profiles

14.1. DNA Fit

14.1.1. Company Overview

14.1.2. Product Offerings

14.1.3. Financial Performance

14.1.4. Recent Initiatives

14.2. Superior Supplement Manufacturing

14.2.1. Company Overview

14.2.2. Product Offerings

14.2.3. Financial Performance

14.2.4. Recent Initiatives

14.3. Metagenetics, Inc.

14.3.1. Company Overview

14.3.2. Product Offerings

14.3.3. Financial Performance

14.3.4. Recent Initiatives

14.4. Asiamerica, Ingredients

14.4.1. Company Overview

14.4.2. Product Offerings

14.4.3. Financial Performance

14.4.4. Recent Initiatives

14.5. Nutralliance, Inc.

14.5.1. Company Overview

14.5.2. Product Offerings

14.5.3. Financial Performance

14.5.4. Recent Initiatives

14.6. Mixfix, Inc.

14.6.1. Company Overview

14.6.2. Product Offerings

14.6.3. Financial Performance

14.6.4. Recent Initiatives

14.7. Barrington Nutritionals

14.7.1. Company Overview

14.7.2. Product Offerings

14.7.3. Financial Performance

14.7.4. Recent Initiatives

14.8. Balchem Corporation

14.8.1. Company Overview

14.8.2. Product Offerings

14.8.3. Financial Performance

14.8.4. Recent Initiatives

14.9. Arizona Nutritional Supplements

14.9.1. Company Overview

14.9.2. Product Offerings

14.9.3. Financial Performance

14.9.4. Recent Initiatives

14.10. Maat Nutritionals

14.10.1. Company Overview

14.10.2. Product Offerings

14.10.3. Financial Performance

14.10.4. Recent Initiatives

Chapter 15. Research Methodology

15.1. Primary Research

15.2. Secondary Research

15.3. Assumptions

Chapter 16. Appendix

16.1. About Us

16.2. Glossary of Terms

Contact Us:

Precedence Research

Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada

Call: +1 774 402 6168

Email: sales@precedenceresearch.com

Website: https://www.precedenceresearch.com

 Blog: https://www.pharma-geek.com